Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece

Gergianaki, Irini; Fanouriakis, Antonis; Repa, Argyro; Tzanakakis, Michail; Adamichou, Christina; Pompieri, A.; Spirou, Giorgis; Bertsias, Antonios; Kabouraki, E.; Tzanakis, Ioannis; Chatzi, Leda; Sidiropoulos, Prodromos; Boumpas, Dimitrios T.; Βertsias, George

doi:10.1136/annrheumdis-2017-211206

Cited by 93 publications

(83 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prior to this study, there was no local up-to-date register of SLE patients and a population based study on SLE had not been described; thus the prevalence and incidence of SLE in Malta was not known. Population based studies in other Mediterranean islands, namely, Sardinia and Crete, have noted a prevalence of SLE of 81 and 123.4 per 100,000, respectively [2, 3]. The incidence of SLE in Crete was reported as 7.4/100,000 per year [3].…”

Section: Introductionmentioning

confidence: 99%

Characterisation of Patients with Systemic Lupus Erythematosus in Malta: A Population Based Cohort Cross-Sectional Study

Magro

Borg

2018

BioMed Research International

View full text Add to dashboard Cite

Systemic Lupus Erythematosus (SLE) is a multisystemic autoimmune disorder. The aim of this study was to characterise the SLE patients living in Malta in order to estimate the prevalence and incidence of SLE and characterise the clinical presentation as well as identify any unmet needs. 107 SLE patients who fulfilled SLICC classification criteria were identified. These were invited to participate in the study by means of an interview, blood and urine tests, and filling of the following questionnaires: Fatigue Severity Scale (FSS), visual analogue scale (VAS) for fatigue, Hospital Anxiety and Depression Scale (HADS), VAS for pain, Pittsburgh Sleep Quality Index (PSQI), and modified Health Assessment Questionnaire (mHAQ). The estimated prevalence of SLE in Malta is 29.3 patients per 100,000 and the estimated incidence is 1.48 per 100,000 per year. 93.5% of SLE patients were female, and the mean age at diagnosis was 33.1 years. 60.8% were overweight or obese and body mass index (BMI) had a significant positive correlation with daily dose of prednisolone (R=0.177, p=0.046). 20.7% and 3.3% had a moderate and high disease activity, respectively, as measured by SLEDAI-2K. Disease activity had a significant positive correlation with functional disability measured by mHAQ (R=0.417, p<0.001). 56.5% had an abnormal level of fatigue (FSS >3.7) and 57.6% had a high level of anxiety (HADS ≥8). This study has identified a number of unmet needs of SLE patients, including obesity, uncontrolled disease activity, fatigue, and anxiety.

show abstract

Section: Introductionmentioning

confidence: 99%

Characterisation of Patients with Systemic Lupus Erythematosus in Malta: A Population Based Cohort Cross-Sectional Study

Magro

Borg

2018

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…By contrast, males tend to suffer from more severe disease. [1][2][3] Understanding the molecular basis of SLE variability and sexual dimorphism may advance our understanding of disease pathogenesis and assist the development of personalized treatments. We performed full transcriptome analysis (RNA-seq) to monitor for differentially expressed genes (DEGs) between male and female SLE patients that are not differentially expressed between male and female healthy subjects, thus identifying a gender-biased molecular signature specific for the disease.…”

Section: Exploring the Molecular Basis Of Gender Bias In Systemic Lupmentioning

confidence: 99%

P108 Exploring the molecular basis of gender bias in systemic lupus erythematosus (SLE)

Kosmara

Panousis

Banos

et al. 2018

Poster Presentations

View full text Add to dashboard Cite

Background/objectivesSLE features a substantially greater frequency in females than in males (ratio ranging 7:1–15:1). By contrast, males tend to suffer from more severe disease.1–3 Understanding the molecular basis of SLE variability and sexual dimorphism may advance our understanding of disease pathogenesis and assist the development of personalized treatments. We performed full transcriptome analysis (RNA-seq) to monitor for differentially expressed genes (DEGs) between male and female SLE patients that are not differentially expressed between male and female healthy subjects, thus identifying a gender-biased molecular signature specific for the disease.Materials and methodsWhole blood RNA was extracted from SLE patients and healthy individuals. Paired-end mRNA sequencing was performed using the Illumina HiSeq2000 platform. A list of DEGs in SLE males versus females were generated using 5% false discovery rate (FDR). To increase the specificity of our results, we generated a similar list of DEGs in healthy males versus females using a 50% and 90% FDR cut-off, and the two lists were intersected.ResultsWe studied 142 SLE patients with diverse levels of disease activity/severity (120 SLE females, 22 SLE males) compared to 58 matched healthy volunteers (48 healthy females, 10 healthy males). We identified 39 genes which were significantly differentially expressed in SLE males versus females. Notably, 6 of these genes were not differentially expressed in healthy males versus females at either 50 or 90% FDR, highlighting a potential role in disease sexual dimorphism. The proteins encoded by these genes are implicated in various biological processes such as transcriptional regulation and DNA damage repair (SMC1A), lipoprotein particles catabolism (APOE), glutathione biosynthesis and metabolism (OPLAH), correct composition of bone and cartilage matrix (ARSD), whereas 2 of these genes do not code for proteins (MTCO2 and FRG1B). Further validation of these genes is in progress.ConclusionsA gender-biased molecular signature specifically associated with SLE was unraveled. Further investigation of the molecular pathways which are associated with these genes will give us insights for the molecular basis of gender bias in SLE and lead to novel, more effective treatments tailored for male and female patients.References. Margery-Muir AA, et al. Gender balance in patients with systemic lupus erythematosus. Autoimmun Rev 2017;16(3):258–268.. Boodhoo KD, Liu S, Zuo X. Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Medicine (Baltimore) 2016;95(29):e4272.. Gergianaki I, et al. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: Data from the community-based lupus registry of Crete, Greece. Ann Rheum Dis 2017.

show abstract

“…1,2 D Kosmara, 3 N Panousis, 4 A Banos, 1,2 P Sidiropoulos, 3 Background/objectives SLE features a substantially greater frequency in females than in males (ratio ranging 7:1-15:1). By contrast, males tend to suffer from more severe disease.…”

Section: Exploring the Molecular Basis Of Gender Bias In Systemic Lupmentioning

confidence: 99%

Section: Exploring the Molecular Basis Of Gender Bias In Systemic Lupmentioning

confidence: 99%

P109 Clinical development of a novel strategy to mitigate biologic immunogenicity: monthly dosing of a pegylated uricase with SVP-R enables sustained reduction of serum uric acid (SUA) levels by mitigating formation of anti-drug antibodies (ADAS)

Sands

Kivitz

DeHaan

et al. 2018

Poster Presentations

View full text Add to dashboard Cite

IntroductionPegylated uricases are a promising but highly immunogenic therapy for severe gout. Preclinical studies have shown the ability of synthetic vaccine particles containing rapamycin (SVP-R) to inhibit the formation of ADAs against pegsiticase, a pegylated uricase.1 Here we report initial data on the safety, immunogenicity and activity of an ongoing Phase 2 study of SEL-212, a novel combination therapy consisting of pegsiticase and SVP-R.ObjectivesEvaluate the ability of monthly doses of SEL-212 to mitigate the immunogenicity of pegsiticase and enable sustained control of sUA in gout patients.MethodsPatients with symptomatic gout and elevated sUA (≥6 mg/dL) were treated with fixed doses of pegsiticase (0.2 mg/kg or 0.4 mg/kg) alone or co-administered with SVP-R (0.05, 0.08, or 0.1 mg/kg). SEL-212 was infused in 28 day cycles x3 doses followed by challenge with pegsiticase alone on 28 day cycles x2 doses. Safety, tolerability, sUA, and ADAs were monitoredResultsIn the SEL-212 Phase 1b study, 70% of patients administered 0.4 mg/kg pegsiticase with a mid-dose of 0.1 mg/kg SVP-R showed low or no ADA formation correlating with sustained low sUA levels for at least 30 days after a single dose, compared to 20% for patients treated with pegsiticase alone. In the ongoing Phase 2 study, the majority of patients receiving 0.1 mg/kg SVP-R administered with either 0.2 or 0.4 mg/kg pegsiticase also showed low or no ADAs and maintained low sUA levels after 3 monthly doses of SEL-212, indicating sustained activity with repeated doses of SEL-212. However after 2 subsequent doses of pegsiticase alone, a drop in activity was noted. These data suggest that either a higher dose of SVP-R or the addition of SVP-R at the 4th and 5th dose may be required to sustain activity through 5 months. Currently patients are being dosed with 0.15 mg/kg SVP-R, a dose level which enabled sustained control of sUA levels in all patients in Phase 1b. SEL-212 was generally well tolerated and associated with a low rate of gout flare rates compared to those treated with pegsiticase alone.ConclusionsSVP-R showed a dose-dependent reduction in ADAs and enabled sustained control of sUA with repeated dosing of SEL-212. SVP-R is a promising approach to prevent the formation of ADAs against immunogenic biologic therapies.Reference. Kishimoto TK, et al. Nature Nanotechnol2016;11:890–899.AcknowledgementsWe thank the patients that participated in these studies, the clinical study site investigators, and the entire SEL-212 project team.Disclosure of interestE. Sands Employee of: Selecta Biosciences, A. Kivitz: None declared, W. DeHaan Employee of: Selecta Biosciences, L. Johnston Employee of: Selecta Biosciences, T. Kishimoto Employee of: Selecta Biosciences

show abstract

Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece

Cited by 93 publications

References 45 publications

Characterisation of Patients with Systemic Lupus Erythematosus in Malta: A Population Based Cohort Cross-Sectional Study

Characterisation of Patients with Systemic Lupus Erythematosus in Malta: A Population Based Cohort Cross-Sectional Study

P108 Exploring the molecular basis of gender bias in systemic lupus erythematosus (SLE)

P109 Clinical development of a novel strategy to mitigate biologic immunogenicity: monthly dosing of a pegylated uricase with SVP-R enables sustained reduction of serum uric acid (SUA) levels by mitigating formation of anti-drug antibodies (ADAS)

Contact Info

Product

Resources

About